Tiamutin therapy by injection and water immediately reduces the clinical signs and subsequent follow-up in-feed medication assures optimal performance to slaughter.
| DOSAGE PROGRAMMES |
| The following standard dosage programmes have been devised: |
| PREMIX |
|
| Therapy |
100 - 200ppm thf/tonne finished feed for 7 - 10 consecutive days. |
| Prevention/control |
30 - 50ppm thf/tonne finished feed continuously for the period of risk. |
| WATER SOLUBLE POWDER/SOLUTION |
| Therapy |
120 - 180mg thf/litre drinking water for 3 - 5 consecutive days. |
| INJECTABLE |
| Therapy |
12.3mg tiamulin base (approx. equivalent to 15.0mg thf) per kg bwt for 3 consecutive days intramuscularly. |
In PRDC the key pathogens are M. hyo together with the PRRS, SIV and PCV-2 viruses and complicating bacteria such as Actinobacillus pleuropneumoniae, Haemophilus parasuis, Streptococcus suis, Pasteurella multocida and Arcanobacterium pyogenes.
The bacterial/mycoplasmal components of this respiratory complex of mixed microbial origin are best controlled with the comprehensive broad spectrum antibacterial/antimycoplasmal activity provided by the premix combination of Tiamutin with chlortetracycline or doxycycline, rather than with Tiamutin alone.
Recent experimental work has clearly demonstrated the efficacy of Tiamutin (100pm) CTC (400pm) premix against mixed M. hyo, Pasteurella multocida (Pm) and Actinobacillus pleuropneumoniae (App) infections, in comparison with tilmicosin (300 ppm). 5-6 weeks old specific pathogen-free piglets were experimentally infected with M. hyo on day 1, on day 8 with Pm and on day 15 with App. The premix treatments started on day 9 and continued for 12 consecutive days. The piglets were then autopsied for examination of macroscopic, histological and pathological lesions and for the presence of mycoplasmas and bacteria in the lungs.
The Tia/CTC group showed an excellent response in average gain (+14.1%) and feed conversion efficiency (22.1% improvement) in comparison with the untreated, infected controls.
When the lungs were examined for the presence of M. hyo it was not possible to recover M. hyo from the Tia/CTC medicated group. However M. hyo was not eliminated from the lungs of the tilmicosin medicated group. [?] (See table below)
| |
Stipkovits, L. and others (2001) |
| Comparative efficacy of Tia/CTC vs tilmicosin against a mixed respiratory infection challenge |
Treatment
group |
Wt. gain
(%) |
Index
(%) |
FCE |
Index
(%) |
Pneumonic
lesion score |
Isolation
of M. hyo. |
Uninfected,
untreated |
10.0 |
100 |
1.93 |
100 |
0% |
0/10 |
Infected,
untreated |
8.85 |
88.5 |
2.44 |
126.4 |
100% |
8/10 |
| Tiamutin/CTC |
10.1 |
101 |
1.90 |
98.4 |
24% |
0/10 |
| Tilmicosin |
9.95 |
99.5 |
1.88 |
94.4 |
40% |
3/10 |
|
Use in Sows
The farrowing process is the most stressful time during a sow’s pregnancy and sows are vulnerable to uterine and mammary infections at farrowing and immediately post-partum. Research conducted over many years reviewed by Cromwell, G.L (1999) [?] has shown that there is a benefit in piglet survival and in weaning weights when sows are fed CTC (440ppm) in the farrowing/lactation diet. The target CTC intake should be 0.5g of CTC/sow/day.
| 
